Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.40 USD
Change Today +0.11 / 2.56%
Volume 31.8K
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

alliqua biomedical inc (ALQA) Snapshot

Open
$4.30
Previous Close
$4.29
Day High
$4.45
Day Low
$4.29
52 Week High
02/9/15 - $6.55
52 Week Low
10/28/14 - $3.70
Market Cap
121.7M
Average Volume 10 Days
40.3K
EPS TTM
$-1.35
Shares Outstanding
27.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALLIQUA BIOMEDICAL INC (ALQA)

Related News

No related news articles were found.

alliqua biomedical inc (ALQA) Related Businessweek News

No Related Businessweek News Found

alliqua biomedical inc (ALQA) Details

Alliqua BioMedical, Inc. provides wound care solutions. The company offers Extracellular Matrix, a suite of advanced wound management products; Biovance, a decellularized and dehydrated allograft for the management of non-infected partial-and full-thickness wounds; SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. It also provides contact dressings, island dressings, and wraps using TheraBond 3D antimicrobial barrier systems. In addition, the company offers Sorbion sachet S, a primary dressing for exudating wounds, such as surgical wounds, venous leg ulcers, and diabetic ulcers; Sorbion sana, a primary wound dressing that provides an another form of wound treatment; and products with hydrokinetic fibers as primary dressings. Further, it provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. Alliqua BioMedical, Inc. primarily serves medical device manufacturers through its direct sales force; and an independent network of agents. The company is headquartered in Langhorne, Pennsylvania.

79 Employees
Last Reported Date: 08/6/15

alliqua biomedical inc (ALQA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $682.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $376.8K
Chief Operating Officer
Total Annual Compensation: $376.8K
Compensation as of Fiscal Year 2014.

alliqua biomedical inc (ALQA) Key Developments

Alliqua Biomedical, Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Fiscal Year Ending December 31, 2015

Alliqua Biomedical, Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenue for the second quarter of 2015 increased $2.1 million, or 202% year-over-year, to $3.1 million. Loss from operations for the second quarter of 2015 was $8.1 million, compared to a loss of $6.2 million for the same period last year. Net loss for the second quarter of 2015 was $7.0 million, or $0.32 per diluted share, compared to a net loss of $6.0 million, or $0.39 per diluted share, last year. Non-GAAP net loss for the second quarter of 2015 was $4.4 million, or $0.20 per diluted share, compared to a non-GAAP net loss of $3.5 million, or $0.23 per diluted share, last year. Net loss before income tax was $8,429,471 compared to $5,950,729 a year ago. For the six months ended June 30, 2015 revenues increased by $3.6 million, or 223%, to $5.2 million from $1.6 million for the six months ended June 30, 2014. For the six months ended June 30, 2015 and 2014, the company had a net loss of $14.7 million, or $0.66 per diluted share, and $15.0 million, or $1.08 per diluted share, respectively. Non-GAAP net loss for the six months of 2015 was $7.8 million, or $0.35 per diluted share, compared to a non-GAAP loss of $7.0 million, or $0.50 per diluted share last year. Net cash flow used in operating activities included approximately $2.8 million of transaction costs related to the Company's acquisition of Celleration during the six months ended June 30, 2015. Changes in working capital increased cash flows used in operating activities by approximately $3.0 million in the six months ended June 30, 2015, compared to the six months ended June 30, 2014. Net loss before income tax was $16,088,228 compared to $14,983,391 a year ago. Purchase of improvements and equipment was $76,738 compared to $6,596 a year ago. For the fiscal year ending December 31, 2015, the company expects total revenue of $16.3 million to $18.8 million, representing growth at the mid-point of the range of approximately 267% year-over-year.

Alliqua BioMedical, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Alliqua BioMedical, Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Aug 06, 2015

Alliqua BioMedical, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Alliqua BioMedical, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALQA:US $4.40 USD +0.11

ALQA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Derma Sciences Inc $5.93 USD +0.02
MiMedx Group Inc $9.60 USD +0.12
Osiris Therapeutics Inc $18.73 USD +0.59
Smith & Nephew PLC 1,163 GBp +29.00
View Industry Companies
 

Industry Analysis

ALQA

Industry Average

Valuation ALQA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.6x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLIQUA BIOMEDICAL INC, please visit alliqua.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.